{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01392105",
      "OrgStudyIdInfo": {
        "OrgStudyId": "MSC2-Version 6.0"
      },
      "Organization": {
        "OrgFullName": "Yonsei University",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction",
      "OfficialTitle": "A Randomized, Open-label, Multicenter Trial for the Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction",
      "Acronym": "SEED-MSC"
    },
    "StatusModule": {
      "StatusVerifiedDate": "July 2009",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 2007"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "May 2010",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "May 2010",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "July 5, 2011",
      "StudyFirstSubmitQCDate": "July 11, 2011",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "July 12, 2011",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "July 11, 2011",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "July 12, 2011",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyOldNameTitle": "Seung-Hwan Lee/Professor",
        "ResponsiblePartyOldOrganization": "Yonsei University Wonju College of Medicine, Wonju Christian Hospital"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Yonsei University",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "FCB-Pharmicell Co Ltd.",
            "CollaboratorClass": "UNKNOWN"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Early reperfusion strategies in tandem with remarkable advances in drugs and devices for treating myocardial infarction (MI) have contributed to a reduction in early mortality, but cardiovascular disease remains the leading cause of death worldwide. Current management strategies cannot solve the problem of cardiomyocyte loss and consequent progression of heart failure. In this respect, stem-cell therapy has shown potential benefits for repairing the damaged myocardium. Mesenchymal stem cells (MSCs) have been considered to be attractive therapeutic candidates because of their high capacity for replication: paracrine effect: ability to preserve potency: and because they do not cause adverse reactions to allogeneic versus autologous transplants. Intracoronary injection of stem cells seems to be safe, but only one clinical trial using MSCs via the intracoronary route in the setting of acute myocardial infarction (AMI) has been carried out. The investigators therefore assessed the safety and efficacy of intracoronary autologous bone marrow (BM)-derived human MSCs in patients with AMI."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Acute Myocardial Infarction"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Mesenchymal stem cells",
          "Myocardial infarction",
          "Left ventricular dysfunction"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2",
          "Phase 3"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "80",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Mesenchymal stem cell treatment group",
            "ArmGroupType": "Active Comparator",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Mesenchymal stem cell"
              ]
            }
          },
          {
            "ArmGroupLabel": "Control group",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "All patients were required to have successful revascularization of an infarct-related artery on coronary angiography at the time of randomization. All patients received aspirin (300 mg loading dose, then 100 mg daily) and clopidogrel (600 mg loading dose, then 75 mg daily) with optimal medical therapy according to the American College of Cardiology (ACC)/ American Heart Association (AHA) guidelines for treatment of ST-segment elevation myocardial infarction (STEMI)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Control group"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Mesenchymal stem cell",
            "InterventionDescription": "Route : intracoronary injection Frequency : single dose of autologous bone-marrow derived mesenchymal stem cells Dosage : 1x1000000 cells/kg Duration : mean injection duration approximately 4 weeks after primary percutaneous coronary intervention",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Mesenchymal stem cell treatment group"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Hearticellgram-AMI"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Control group",
            "InterventionDescription": "No additional treatment of mesenchymal stem cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Control group"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Absolute changes in global LVEF by SPECT",
            "PrimaryOutcomeDescription": "Absolute changes in global left ventricular ejection fraction (LVEF) as measured by SPECT 6 months after cell infusion",
            "PrimaryOutcomeTimeFrame": "baseline and 6 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Changes in left ventricular end-diastolic volume (LVEDV)",
            "SecondaryOutcomeTimeFrame": "baseline and 6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Changes in left ventricular end-systolic volume (LVESV)",
            "SecondaryOutcomeTimeFrame": "baseline and 6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Changes in regional wall motion score index (WMSI) by Echocardiography",
            "SecondaryOutcomeTimeFrame": "baseline and 6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Major adverse cardiac event (MACE)",
            "SecondaryOutcomeDescription": "MACE was defined as the composites of any cause of death, myocardial infarction, revascularization of the target vessel, re-hospitalization for heart failure, and life-threatening arrhythmia.",
            "SecondaryOutcomeTimeFrame": "6 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\naged 18-70 years\nischemic chest pain for >30 min\nadmitted to hospital <24 h after the onset of chest pain\nelectrocardiography showed ST segment elevation >1 mm in two consecutive leads in the limb leads or >2 mm in the precordial leads\nthey could be enrolled in the study <72 h after successful revascularization\n\nExclusion Criteria:\n\ncardiogenic shock (defined as systolic blood pressure <90 mmHg requiring intravenous pressors or intra-aortic balloon counterpulsation)\nlife-threatening arrhythmia\nimpossible conditions for cardiac catheterization\nadvanced renal or hepatic dysfunction\nhistory of previous coronary artery bypass graft\nhistory of hematologic disease\nhistory of malignancy\nmajor bleeding requiring blood transfusion\nstroke or transient ischemic attack in the previous 6 months\nstructural abnormalities of the central nervous system (brain tumor, aneurysm, history of surgery)\ntraumatic injury after myocardial infarction\nuse of corticosteroids or antibiotics during the previous month\nmajor surgical procedure in the previous 3 months\ncardiopulmonary resuscitation for >10 min within the previous 2 weeks\npositive skin test for penicillin\npositive result for viral markers (human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and Venereal Disease Research Laboratory (VDRL) test)\npregnancy, possible candidate for pregnancy or breastfeeding females\ndrug abusers\ninappropriate patients to participate in the study according to the chief investigator",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "70 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Seung-Hwan Lee, MD, PhD",
            "OverallOfficialAffiliation": "Yonsei University Wonju College of Medicine, Wonju Christian Hospital",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Yonsei University Wonju College of Medicine, Wonju Christian Hospital",
            "LocationCity": "Wonju",
            "LocationState": "Gangwon-do",
            "LocationZip": "220-701",
            "LocationCountry": "Korea, Republic of"
          },
          {
            "LocationFacility": "Inha University Hospital",
            "LocationCity": "Inchon",
            "LocationZip": "400-711",
            "LocationCountry": "Korea, Republic of"
          },
          {
            "LocationFacility": "Yonsei Cardiovascular Center and Cardiovascular Research Institute, Yonsei University College of Medicine",
            "LocationCity": "Seoul",
            "LocationZip": "120-752",
            "LocationCountry": "Korea, Republic of"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "24431901",
            "ReferenceType": "derived",
            "ReferenceCitation": "Lee JW, Lee SH, Youn YJ, Ahn MS, Kim JY, Yoo BS, Yoon J, Kwon W, Hong IS, Lee K, Kwan J, Park KS, Choi D, Jang YS, Hong MK. A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction. J Korean Med Sci. 2014 Jan;29(1):23-31. doi: 10.3346/jkms.2014.29.1.23. Epub 2013 Dec 26."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009203",
            "ConditionMeshTerm": "Myocardial Infarction"
          },
          {
            "ConditionMeshId": "D000007238",
            "ConditionMeshTerm": "Infarction"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000007511",
            "ConditionAncestorTerm": "Ischemia"
          },
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000009336",
            "ConditionAncestorTerm": "Necrosis"
          },
          {
            "ConditionAncestorId": "D000017202",
            "ConditionAncestorTerm": "Myocardial Ischemia"
          },
          {
            "ConditionAncestorId": "D000006331",
            "ConditionAncestorTerm": "Heart Diseases"
          },
          {
            "ConditionAncestorId": "D000002318",
            "ConditionAncestorTerm": "Cardiovascular Diseases"
          },
          {
            "ConditionAncestorId": "D000014652",
            "ConditionAncestorTerm": "Vascular Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M11307",
            "ConditionBrowseLeafName": "Myocardial Infarction",
            "ConditionBrowseLeafAsFound": "Myocardial Infarction",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9434",
            "ConditionBrowseLeafName": "Infarction",
            "ConditionBrowseLeafAsFound": "Infarction",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M19977",
            "ConditionBrowseLeafName": "Ventricular Dysfunction",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M19744",
            "ConditionBrowseLeafName": "Ventricular Dysfunction, Left",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9695",
            "ConditionBrowseLeafName": "Ischemia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11436",
            "ConditionBrowseLeafName": "Necrosis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5698",
            "ConditionBrowseLeafName": "Coronary Artery Disease",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M18658",
            "ConditionBrowseLeafName": "Myocardial Ischemia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8571",
            "ConditionBrowseLeafName": "Heart Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16552",
            "ConditionBrowseLeafName": "Vascular Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M3700",
            "InterventionBrowseLeafName": "Aspirin",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M1669",
            "InterventionBrowseLeafName": "Clopidogrel",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M186752",
            "InterventionBrowseLeafName": "Remestemcel-l",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Antipy",
            "InterventionBrowseBranchName": "Antipyretics"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infl",
            "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "ARhu",
            "InterventionBrowseBranchName": "Antirheumatic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "FiAg",
            "InterventionBrowseBranchName": "Fibrinolytic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "Analg",
            "InterventionBrowseBranchName": "Analgesics"
          },
          {
            "InterventionBrowseBranchAbbrev": "PlAggInh",
            "InterventionBrowseBranchName": "Platelet Aggregation Inhibitors"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infe",
            "InterventionBrowseBranchName": "Anti-Infective Agents"
          }
        ]
      }
    }
  }
}